MICHAEL PICKERT: Open Payments
NPI 1275090300 · IRVINGTON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,643 in 107 payments from 15 companies in 2025. Trend: 2023 $3,230 · 2024 $1,139 · 2025 $2,643
Food & beverage: $2,643
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $441 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $396 |
| ABBVIE INC. | 28 | $395 |
| Neurocrine BioSciences, Inc. | 10 | $365 |
| E.R. Squibb & Sons, L.L.C. | 6 | $194 |
| Otsuka America Pharmaceutical, Inc. | 10 | $173 |
| Teva Pharmaceuticals USA, Inc. | 2 | $156 |
| Supernus Pharmaceuticals, Inc. | 8 | $142 |
| Janssen Pharmaceuticals, Inc | 4 | $103 |
| Lundbeck LLC | 4 | $77 |
Products named: Auvelity, CAPLYTA, VRAYLAR, INGREZZA, REXULTI, COBENFY, Qelbree, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
